Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05230537 · ClinicalTrials.gov registry record · Phase 2

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

A Phase 2 study of Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
170
Enrollment target
20
Study locations

NCT05230537 is a Phase 2 study of Age-related Macular Degeneration that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 170 participants, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05230537, a Phase 2 study of Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
170 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.

Conditions Studied

Age-related Macular Degeneration

Interventions

  • DRUG Placebo
  • DRUG Iptacopan (LNP023)

Study Locations (20)

California

  • Retina Consultants of Orange County - Fullerton
  • Salehi Retina Institute - Huntington Beach
  • Martel Eye Medical Group - Rancho Cordova
  • Retinal Consultants Medical Group Inc - Sacramento
  • California Retina Consultants - Santa Barbara

Florida

  • Advanced Research LLC - Deerfield Beach
  • Retina Center Of South Florida - Delray Beach
  • Retina Vitreous Associates of Florida - St. Petersburg

Texas

  • Austin Research Center for Retina - Austin
  • Retina Consultants TX Rsrch Ctr - Bellaire
  • Retina Foundation - Dallas

Colorado

  • Southwest Retina Research Center - Durango

Indiana

  • Midwest Eye Institute - Indianapolis

Louisiana

  • Retina Associates New Orleans - New Orleans

Maryland

  • Retina Care Center - Baltimore

Massachusetts

  • Opthamalic Consultants of Boston - Boston

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2022-02-17
Est. Completion 2026-10-02
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05230537

The ClinicalTrials.gov registry entry for NCT05230537 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (89% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05230537 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT05230537 about?

NCT05230537 is a clinical study titled "A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration". The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.

What is the current status of trial NCT05230537?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2022-02-17. Estimated completion is 2026-10-02.

What conditions does trial NCT05230537 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration.

What interventions are being tested in trial NCT05230537?

The interventions under investigation include: Placebo (DRUG), Iptacopan (LNP023) (DRUG).

Who is sponsoring clinical trial NCT05230537?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05230537 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Age-related Macular Degeneration

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.